Education
About Us
Working with TipRanks
Follow Us
Geron Corporation (GERN)
:GERN
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -25.74%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
The call highlights significant achievements such as FDA approval and strong cash reserves, but also emphasizes challenges like flat revenue trends and the need for strategic adjustments. The sentiment is mixed, with both positive progress and areas needing improvement.Company Guidance
During the Geron Corporation's fourth quarter and full year 2024 earnings call, the management provided detailed guidance on their financial performance and strategic initiatives. RYTELO, Geron's first-in-class telomerase inhibitor, achieved FDA approval in June 2024 and generated $47.5 million in net product revenue in Q4, contributing to a total of $76.5 million since its launch. Despite early success, the company observed flat revenue trends, prompting strategic changes, including leadership updates and targeted efforts to increase new patient starts across different treatment lines. Geron ended 2024 with approximately $503 million in cash, projecting a strong financial position to reach profitability without additional financing, contingent upon meeting internal sales and operating expense expectations. Furthermore, the company highlighted ongoing development in myelofibrosis, with 80% enrollment in the pivotal Phase 3 IMpactMF trial, anticipating key interim and final analyses in 2026 and 2028, respectively, which could potentially double RYTELO's commercial opportunity.FDA Approval and Market Launch of RYTELO
RYTELO, a first-in-class telomerase inhibitor, was approved by the FDA in June 2024 and launched in the U.S. for the treatment of lower-risk MDS patients. It achieved $76.5 million in net product revenue by year-end, surpassing internal expectations.
Strong Cash Position
Geron ended the year with approximately $503 million in cash, cash equivalents, restricted cash, and marketable securities, positioning the company to potentially reach profitability without additional financing.
Favorable Regulatory Developments in Europe
The CHMP adopted a positive opinion recommending RYTELO's approval in Europe, with a final decision expected from the European Commission in the first half of 2025.
Pipeline Progress in Myelofibrosis
80% enrollment achieved in the pivotal Phase 3 IMpactMF trial for imetelstat in JAKi relapsed/refractory myelofibrosis, with interim analysis expected in the second half of 2026.
---
GERN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GERN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $2.37 | $1.61 | -32.07% |
| Nov 07, 2024 | $4.27 | $4.29 | +0.47% |
| Aug 08, 2024 | $4.56 | $4.60 | +0.88% |
| May 02, 2024 | $4.08 | $3.95 | -3.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Geron Corporation (GERN) report earnings?
Geron Corporation (GERN) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Geron Corporation (GERN) earnings time?
Geron Corporation (GERN) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GERN EPS forecast?
GERN EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---